Ticagrelor is a novel oral antiplatelet agent. It can inhibit platelet aggregation mediated by adenosine diphosphate (ADP) by directly acting on ADP receptor P2Y12, exerting its antiplatelet function. In addition, ticagrelor showed bioavailability like increasing coronary blood flow, reducing myocardial infarction size and inducing dyspnea. These effects were thought to be closely related to adenosine. However, recent publications about the effect of ticagrelor on plasma adenosine concentration were inconsistent, which may be caused by different determination methods, especially various compositions of stop solution, and different sampling time points. Standardized determination method of plasma adenosine concentration and dynamically monitoring the changes of plasma adenosine after taking ticagrelor may help to further illustrate the influence of ticagrelor on plasma adenosine concentration.